Successful use of aflibercept for high cardiac output in hereditary hemorrhagic telangiectasia after failure of pazopanib and bevacizumab therapy, Journal of Thrombosis and Haemostasis, (2025 ...

Benign hereditary telangiectasia is an inherited condition that causes dilated blood vessels on your skin and lips. Unlike other similar conditions, it does not cause any systemic symptoms. Benign ...

HealthDay News — For patients with hereditary hemorrhagic telangiectasia (HHT), pomalidomide yields a significant reduction in epistaxis severity, according to a study published in the September ...

Case report: Diagnosis of hereditary hemorrhagic telangiectasia (Osler Weber Rendu syndrome) in a 23-year-old male presented with anemia and thrombocytopenia and its response to bevacizumab. https ...

‘#Hereditary_hemorrhagic_telangiectasia (HHT) is a rare #bleeding disorder that affects more than 1 in 5,000 individuals globally. #medindia ’ A single patient sparked this trial.

Study conducted in partnership with Cure HHT will inform future clinical trials and treatment options for people living with HHT Company recently progressed DIAG723 into IND-enabling studies for ...

About Hereditary Hemorrhagic Telangiectasia (HHT) ‍HHT is a rare disease that affects more than 150,000 people in the U.S. and EU, and for which there are currently no approved therapies.

Diagonal Therapeutics Inc.’s DIAG-723 has been awarded orphan drug designation by the FDA for the treatment of hereditary hemorrhagic telangiectasia (HHT). Additionally, the EMA has provided a ...

WATERTOWN, Mass. , March 04, 2025 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company focused on correcting dysregulated signaling with multispecific antibodies that address the ...